4-methyl-1,5-diphenyl-1H-pyrazole-3-carboxylic acid | 112009-32-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 4-methyl-1,5-diphenyl-1H-pyrazole-3-carboxylic acid
• 英文别名: 4-methyl-1,5-diphenylpyrazole-3-carboxylic acid
• CAS: 112009-32-2
• 化学式: C₁₇H₁₄N₂O₂
• 分子量: 278.31
• InChiKey: ZUKBYBCXGPIXFT-UHFFFAOYSA-N

物化性质

• 沸点：
  484.7±33.0 °C(Predicted)
• 密度：
  1.21±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  21
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.06
• 拓扑面积：
  55.1
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-methyl-1,5-diphenyl-1H-pyrazole-3-carboxylic acid 在 氯化亚砜 、 N,N-二异丙基乙胺 作用下， 以 氯仿 、 甲苯 为溶剂， 反应 6.5h， 生成 4-methyl-1,5-diphenyl-N-(1-piperidinyl)-1H-pyrazole-3-carboxamide
  参考文献：
  名称：

  Synthesis, hypoglycemic activity and molecular modeling studies of pyrazole-3-carbohydrazides designed by a CoMFA model

  摘要：

  Diabetes and obesity are two universal health problems that constitute a research objective of several groups due to the lack of efficient and safe drug treatment. In this sense, cannabinoid receptor 1 (CBI) has attracted interest because of its role in food intake and metabolic balance, two targets in the control of metabolic syndrome. In this work, novel 1,5-diaryl pyrazole derivatives were synthesized in accordance with the pKi prediction of a previously reported CoMFA model by our group. To further investigate the biological activity of these compounds in metabolic disorders, their hypoglycemic activity in an in vivo model was tested. Interestingly, a high degree of correlation was observed between the predicted pK(i) and hypoglycemic effect 7 h after administration. Compounds 4, 9 and 13 showed the most significant plasma glucose reduction with decreases of 60%, 64% and 60% respectively. This result not only surpasses the activity of the lead rimonabant, but also that of the reference drug glibenclamide. Moreover, PASS prediction and molecular docking in an excellent validated homology model of CBI suggest that these compounds would probably act as CBI antagonists/inverse agonists and therefore, antiobesity agents. The ligand receptor complexes demonstrate that 1,5-diaryl pyrazole derivatives bind to the proposed binding site where a hydrophobic moiety interacts with the phenyl rings in the pyrazole nucleus and Lys192 forms a hydrogen bond with the oxygen of the carbonyl group. Dynamics simulations were also carried out to study the stability of the ligand receptor complexes where the most active compounds showed smaller Delta G values and more hydrogen bonds throughout the simulation. These compounds are considered useful leads for further optimization in the treatment of such metabolic illnesses. (C) 2013 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2013.07.054
• 作为产物：
  描述：

  ethyl 4-methyl-1,5-diphenyl-1H-pyrazole-3-carboxylate 在 sodium hydroxide 作用下， 以 乙醇 、 水 为溶剂， 反应 4.0h， 以1.01 g的产率得到4-methyl-1,5-diphenyl-1H-pyrazole-3-carboxylic acid
  参考文献：
  名称：

  “One-Pot” Synthesis of 4-Substituted 1,5-Diaryl-1H-pyrazole-3-carboxylic Acids via a MeONa/LiCl-Mediated Sterically Hindered Claisen Condensation–Knorr Reaction–Hydrolysis Sequence

  摘要：

  A "one-pot" synthesis of 4-substituted 1,5-diaryl-1H-pyrazole-3-carboxylic acids was first reported in moderate to good yields. This concise procedure, featuring efficiency and green chemistry, was composed of MeONa/LiCl-mediated sterically hindered Claisen condensation, Knorr reaction and hydrolysis.

  DOI：

  10.1055/s-0032-1317668

文献信息

• Process for the preparation of 1,5 - carboxylic acid derivatives
  申请人：DAUMAS Marc

  公开号：US20070099978A1

  公开（公告）日：2007-05-03

  The present invention comprises a process for the preparation of compounds that possess an affinity for the cannabinoid receptor in the human brain. These compounds are useful as immunomodulators and psychotropic agents in the treatment of thymic disorders, vomiting, myo-relaxation, various types of neuropathy, memory disorders, dyskinesia, migraine, asthma, epilepsy, glaucoma, anticancer chemotherapy, in ischemia and angina, in orthostatic hypotension and in cardiac distress. More specifically, the present invention comprises a process for the preparation of a series of compounds of formula (I): in which R 1 -R 7 and W represent various alkyl groups and the derivatives thereof and are more specifically are defined herein.

  本发明涉及一种用于制备具有亲和力的化合物的方法，这些化合物在人类大脑中与大麻素受体结合。这些化合物可用作免疫调节剂和精神药物，用于治疗胸腺疾病、呕吐、肌肉松弛、各种类型的神经病、记忆障碍、运动障碍、偏头痛、哮喘、癫痫、青光眼、抗癌化疗、缺血和心绞痛、直立性低血压以及心脏困扰。更具体地，本发明涉及一种用于制备一系列化合物的方法，其化学式为（I）：其中R1-R7和W代表各种烷基基团及其衍生物，更具体地在此处定义。
• Pyrazole derivative
  申请人：Kanaya Naoaki

  公开号：US20060128685A1

  公开（公告）日：2006-06-15

  The present invention is directed to a strong platelet aggregation-inhibiting agent which does not inhibit COX-1 or COX-2. The present invention provides compounds represented by formula (I) or formula (II), salts of the compounds, and solvates of the compounds or the salts. Also provided are medicaments containing any of the compounds, salts, or solvates and preventive and/or therapeutic agents for ischemic diseases, containing any of the compounds, salts, or the solvates.

  本发明旨在提供一种强的血小板聚集抑制剂，其不抑制COX-1或COX-2。本发明提供了由式（I）或式（II）表示的化合物，化合物的盐以及化合物或盐的溶剂。还提供了包含任何一种化合物、盐或溶剂的药物以及预防和/或治疗缺血性疾病的制剂，其中包含任何一种化合物、盐或溶剂。
• “One-Pot” Synthesis of 4-Substituted 1,5-Diaryl-1H-pyrazole-3-carboxylic Acids via a MeONa/LiCl-Mediated Sterically Hindered Claisen Condensation–Knorr Reaction–Hydrolysis Sequence
  作者：Ya-Fei Ji、Jian-An Jiang、Cai-Yan Du、Chun-Hui Gu

  DOI：10.1055/s-0032-1317668

  日期：——

  A "one-pot" synthesis of 4-substituted 1,5-diaryl-1H-pyrazole-3-carboxylic acids was first reported in moderate to good yields. This concise procedure, featuring efficiency and green chemistry, was composed of MeONa/LiCl-mediated sterically hindered Claisen condensation, Knorr reaction and hydrolysis.
• PYRAZOLE DERIVATIVE
  申请人：Daiichi Sankyo Company, Limited

  公开号：EP1591443B1

  公开（公告）日：2010-08-25
• Development of Yin-Yang ligand for cannabinoid receptors
  作者：Yanli Qiu、Yitian Zhao、Tao Hu、Meifang Yang、Fei Li、Cuixia Li、Weiliang Gu、Xiaodi Yang、Suwen Zhao、Houchao Tao

  DOI：10.1016/j.bioorg.2023.106377

  日期：2023.4